Back to top
more

Anavex Life Sciences (AVXL)

(Delayed Data from NSDQ)

$3.87 USD

3.87
702,147

-0.16 (-3.97%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AVXL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Anavex Life Sciences Corp. [AVXL]

Reports for Purchase

Showing records 121 - 140 ( 155 total )

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 121

06/08/2019

Company Report

Pages: 3

We are terminating coverage of Anavex Life Sciences Corp. due to the departure from the firm of the covering analyst.

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEDE K

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 122

05/23/2019

Company Report

Pages: 4

Effective with this report we are transferring coverage to Scott Henry, CFA, and maintaining our Buy rating and $10 price target.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 123

05/23/2019

Industry Report

Pages: 3

Coverage Update - Healthcare Sector

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 124

05/10/2019

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 125

05/09/2019

Company Report

Pages: 6

Rett Program Expands Down Under

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 126

03/24/2019

Industry Report

Pages: 5

Healthcare - Beyond the Rise and Fall of Amyloid

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 127

02/08/2019

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 128

02/08/2019

Company Report

Pages: 6

Spotlight on Rett as Wider Pipeline Advances

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 129

01/28/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 130

01/28/2019

Company Report

Pages: 13

Sigma-ture Neurology; Resuming with Buy

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 50.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 131

10/31/2018

Company Report

Pages: 4

Parkinson''s Disease Dementia - First Person Enrolled

Provider: H.C. Wainwright & Co., Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 132

10/22/2018

Company Report

Pages: 4

The FDA Approves the Start for Phase 2 Trial of ANAVEX2-73 in Rett Syndrome

Provider: H.C. Wainwright & Co., Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 133

09/07/2018

Industry Report

Pages: 3

Healthcare: Coverage Update

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 134

09/07/2018

Company Report

Pages: 4

We are placing shares of AVXL Under Review, and transferring coverage to ROTH Capital Research due to the departure of the covering analyst.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 135

08/28/2018

Company Report

Pages: 4

First Patient Enrolled in the Phase 2b/3 Alzheimer''s Study; PDD and Rett Syndrome are Coming Too

Provider: H.C. Wainwright & Co., Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 136

08/10/2018

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 137

08/10/2018

Company Report

Pages: 6

3Q18 Financial Report As Expected; 2H18 Clinical Milestones Confirmed

Provider: Roth Capital Partners, Inc.

Analyst: LEBOYER R

Price: 25.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 138

08/10/2018

Company Report

Pages: 5

Three Trials Starting This Year With Cash Through the Next Set of Catalysts

Provider: H.C. Wainwright & Co., Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 139

07/26/2018

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 140

07/26/2018

Company Report

Pages: 6

AAIC Presentations Show Genetic Marker Data And Trial Design

Provider: Roth Capital Partners, Inc.

Analyst: LEBOYER R

Price: 25.00

Research Provided by a Third Party